MANGALAM — Mangalam Drugs and Organics Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual income statement for Mangalam Drugs and Organics, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	4,511	3,723	3,686	3,182	2,321
Cost of Revenue
Gross Profit	1,170	915	923	1,194	753
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4,123	3,577	3,658	2,987	2,653
Operating Profit	388	145	28.1	196	-331
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	277	22.1	-111	47.9	-486
Provision for Income Taxes
Net Income After Taxes	197	12.7	-90.5	67.2	-444
Net Income Before Extraordinary Items
Net Income	197	12.7	-90.5	67.2	-444
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	197	12.7	-90.5	67.2	-444
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	12.4	0.804	-5.7	4.22	-28.1